Delta-Fly Pharma Prepares FDA Talks on AML Drug DFP-10917
MT Newswires Live
Apr 16
Delta-Fly Pharma (TYO:4598) is preparing to begin discussions with the U.S. FDA on its AML drug DFP-10917 following clinical trial results, according to a Thursday filing on the Tokyo Stock Exchange.
An interim Phase 3 study of monotherapy did not meet its primary endpoint but showed higher response rates and signs of survival benefit in certain subgroups.
Combination therapy with venetoclax demonstrated response rates above 50% in early-stage trials, with some patients moving to stem cell transplants.
The company is also in talks with overseas pharmaceutical firms for potential co-development and global trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.